コンテンツへスキップ
Merck
  • Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.

Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.

Gastroenterology (2014-03-04)
Yijin Wang, Xinying Zhou, Yannick Debing, Kan Chen, Luc J W Van Der Laan, Johan Neyts, Harry L A Janssen, Herold J Metselaar, Maikel P Peppelenbosch, Qiuwei Pan
要旨

Many recipients of organ transplants develop chronic hepatitis, due to infection with the hepatitis E virus (HEV). Although chronic HEV infection is generally associated with immunosuppressive therapies, little is known about how different immunosuppressants affect HEV infection. A subgenomic HEV replication model, in which expression of a luciferase reporter gene is measured, and a full-length infection model were used. We studied the effects of different immunosuppressants, including steroids, calcineurin inhibitors (tacrolimus [FK506] and cyclosporin A), and mycophenolic acid (MPA, an inhibitor of inosine monophosphate dehydrogenase) on HEV replication in human hepatoma cell line Huh7. Expression of cyclophilins A and B (the targets of cyclosporin A) were knocked down using small hairpin RNAs. Steroids had no significant effect on HEV replication. Cyclosporin A promoted replication of HEV in the subgenomic and infectious models. Knockdown of cyclophilin A and B increased levels of HEV genomic RNA by 4.0- ± 0.6-fold and 7.2- ± 1.9-fold, respectively (n = 6; P < .05). A high dose of FK506 promoted infection of liver cells with HEV. In contrast, MPA inhibited HEV replication. Incubation of cells with guanosine blocked the antiviral activity of MPA, indicating that the antiviral effects of this drug involve nucleotide depletion. The combination of MPA and ribavirin had a greater ability to inhibit HEV replication than MPA or ribavirin alone. Cyclophilins A and B inhibit replication of HEV; this might explain the ability of cyclosporin A to promote HEV infection. On the other hand, the immunosuppressant MPA inhibits HEV replication. These findings should be considered when physicians select immunosuppressive therapies for recipients of organ transplants who are infected with HEV.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
デキサメタゾン, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
デキサメタゾン, ≥98% (HPLC), powder
Sigma-Aldrich
カリウム, chunks (in mineral oil), 98% trace metals basis
USP
タクロリムス, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
プレドニゾロン, ≥99%
Sigma-Aldrich
水素化カリウム, 30 wt % dispersion in mineral oil
Sigma-Aldrich
デキサメタゾン, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
デキサメタゾン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
FK-506 一水和物, ≥98% (HPLC)
USP
プレドニゾロン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
水素化カリウム, in paraffin
Sigma-Aldrich
デキサメタゾン, meets USP testing specifications
Supelco
デキサメタゾン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
プレドニゾロン, Pharmaceutical Secondary Standard; Certified Reference Material
プレドニゾロン, European Pharmacopoeia (EP) Reference Standard
Supelco
プレドニゾロン, VETRANAL®, analytical standard
Sigma-Aldrich
デキサメタゾン, tested according to Ph. Eur.
Supelco
デキサメタゾン, VETRANAL®, analytical standard
デキサメタゾン, European Pharmacopoeia (EP) Reference Standard
デキサメタゾン, British Pharmacopoeia (BP) Assay Standard
システム適合性用デキサメタゾン, European Pharmacopoeia (EP) Reference Standard
デキサメタゾン, European Pharmacopoeia (EP) Reference Standard
プレドニゾロン, British Pharmacopoeia (BP) Assay Standard
システム適合性用プレドニゾロン, European Pharmacopoeia (EP) Reference Standard
プレドニゾロン, European Pharmacopoeia (EP) Reference Standard